The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose-Lmiting Toxicity (DLT),
Timeframe: From time of first dose of QLS1317 to end of DLT period (25 days)
Maximum Tolerated Dose (MTD)
Timeframe: 1 year
Recommended Phase ll Dose（RP2D）
Timeframe: 2 years
Objective Remission Rate (ORR)
Timeframe: 2 years